The 5 Dumbest Things on Wall Street This Week: June 1
5. Vertex Shall Meet Twain
Forgive us Mark Twain, but when it comes to Vertex Pharmaceuticals (VRTX) recent meltdown, it's less about "lies, damn lies and statistics" than a case of stupidity, damn stupidity and statistics.
Shares of Vertex tumbled 11% Tuesday, after the high-flying biotech released corrected data involving its cystic fibrosis treatments that drastically reduced the number of patients who showed better lung function. Back on May 7, the company's stock shot up 55% after Vertex released a far rosier set of figures, which at the time inflated investor hopes that Vertex was indeed close to introducing an effective, not to mention profitable, therapy to fight the life-threatening genetic disorder.
Oh lord, that's just ridiculous. To paraphrase the great Twain once again: What a bunch of jackasses! Or maybe it was Samuel Clemens who said that line, we aren't quite sure. We always get those two guys mixed up. Seriously though, we are quite certain that Vertex is trying to shift the blame for the statistical screw-up that sent its stock on its own version of a wild Mississippi river ride. The company swears the error was the result of a vendor's misinterpretation of the data, not its own. "This mistake is very disappointing," said CEO Jeffrey Leiden on a conference call with analysts. "It's unacceptable to us." Give us a break Jeffrey. What's really unacceptable is that fact that you didn't double-check the denominator yourself before going public with the findings. So the next time you have market-moving news to deliver, we suggest you follow Twain's timeless advice and "get your facts first and then you can distort them as much as you wish." Not the other way around.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV